For a second consecutive year, ICCAS\u2019 Status Seminar was held virtually with more than 100 participants on March 10, 2022.
\nDespite 2021 being another challenging year overshadowed by the COVID-19 pandemic, ICCAS\u2019 research teams were able to successfully complete six projects, while also kick-starting eight new ones with public and industrial funding amounting to more than 2.3 million euros.
\nThe BMBF-funded joint project MR-Biopsy by our research group on MR-guided Interventions under the scientific leadership of Prof. Dr. Andreas Melzer, in collaboration with the University of Leipzig Medical Center, University G\u00f6ttingen and led by the industry partner EPflex Feinwerktechnik GmbH, is among the successfully completed projects. A novel design of an MR compatible flexible biopsy forceps and the related clinical workflow for MRI-guided endomyocardial biopsy were developed within the project, both of which now are going to be tested in preclinical studies.
\nAt the same time, within the scope of the LYSiS project under the scientific leadership of PD Dr. Claire Chalopin, an algorithm for automatic tissue classification using artificial intelligence approaches was successfully integrated into the endoscopic HSI system developed by our industrial partner Diaspective Vision GmbH. The TIVITA\u00ae Mini system was certified for the clinical use and a prototype is currently being evaluated at the hospital on patients during operations.
\nMeanwhile, new projects have been launched with focus on applications of Artificial Intelligence (AI), Big Data and 5G and 6G telecommunication standards in the medical-technical field. For instance, the GAIA-X Digital Patient Model (DPM) project under the scientific leadership of Prof. Dr. Thomas Neumuth aims to integrate the technology of a DPM into the GAIA-X ecosystem and, thereby, share pseudonymised population-based data, trained models and analysis modules between institutions and countries inside the EU.
\nFinally, we are excited to announce that the PostStroke-Manager concept by the Biomedical Data Analysis group under the scientific leadership of Prof. Dr. Galina Ivanova in collaboration with the University of Leipzig Medical Center is undergoing a feasibility study.<\/p>\n